                         SEQUENCE LISTING

<110>  Yeda Research and Development Co. Ltd.
       University of Maryland
       EREZ, Ayelet
       RUPPIN, Eytan
       LEE, Joo Sang
       KARATHIA, Hiren
       HANNENHALLI, Sridhar
 
<120>  METHODS OF PROGNOSING AND TREATING CANCER

<130>  73054

<150>  62/470,278
<151>  2017-03-12

<160>  27    

<170>  PatentIn version 3.5

<210>  1
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  1

Gly Arg Pro Asp Ala Glu Tyr 
1               5           


<210>  2
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  2

Val Cys Ser Cys Phe Ile Pro Phe 
1               5               


<210>  3
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  3

Ala Leu Pro Val Leu Ala Ser Pro Ala Tyr 
1               5                   10  


<210>  4
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  4

Gln Pro Lys Arg Glu Cys His Phe 
1               5               


<210>  5
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  5

Thr Ala Ala Asp Thr Ala Ala Gln Ile Thr Gln Arg 
1               5                   10          


<210>  6
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  6

Ala Leu Pro Val Leu Ala Ser Pro Ala Tyr 
1               5                   10  


<210>  7
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  7

Ala Val Thr Glu Leu Gly Arg Pro Asp Ala Glu Tyr 
1               5                   10          


<210>  8
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  8

Glu Asp Arg Arg Ala Ala Val Asp Thr 
1               5                   


<210>  9
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  9

Gly Arg Pro Asp Asp Glu Tyr 
1               5           


<210>  10
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  10

Val Cys Ser Cys Phe Met Pro Phe 
1               5               


<210>  11
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  11

Val Leu Pro Val Leu Ala Ser Leu Ala Tyr 
1               5                   10  


<210>  12
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  12

Gln Leu Lys Arg Glu Cys Gln Phe 
1               5               


<210>  13
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  13

Gln Pro Met Trp Glu Cys Gln Phe 
1               5               


<210>  14
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  14

Gln His Lys Met Glu Cys Gln Phe 
1               5               


<210>  15
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  15

Thr Ala Ala Asp Arg Ala Ala Gln Ile Thr Pro Gly 
1               5                   10          


<210>  16
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  16

Thr Ala Ala Asp Thr Ala Ala Gln Val Thr Pro Gly 
1               5                   10          


<210>  17
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  17

Thr Ala Ala Asp Thr Gly Ala Gln Ile Thr Pro Gly 
1               5                   10          


<210>  18
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  18

Val Leu Pro Val Leu Ala Ser Leu Ala Tyr 
1               5                   10  


<210>  19
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  19

Ala Ala Thr Glu Leu Gly Arg Pro Asp Ala Glu His 
1               5                   10          


<210>  20
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  20

Ala Ala Thr Lys Leu Gly Arg Pro Asp Ala Glu His 
1               5                   10          


<210>  21
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  21

Ala Ala Thr Glu Leu Gly Arg Pro Asn Ala Glu His 
1               5                   10          


<210>  22
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  22

Ala Ala Thr Glu Leu Gly Arg Pro Asp Ala Gln His 
1               5                   10          


<210>  23
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  23

Glu Glu Thr Arg Ala Glu Val Asp Thr 
1               5                   


<210>  24
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  24

Glu Leu Ser Glu Gln Gln Glu Gly Gln Leu 
1               5                   10  


<210>  25
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  25

Lys Glu Glu Glu Glu Ala Glu Asp Lys 
1               5                   


<210>  26
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  26

Glu Leu Ser Glu Gln Gln Glu Gly Gln Leu 
1               5                   10  


<210>  27
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  neo-antigens peptide sequence

<400>  27

Lys Glu Glu Glu Glu Ala Glu Asp Lys 
1               5                   


